Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.56 |
| ▸ | WNT3A | P56704 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.51 |
| ▸ | CKS1B | P61024 | 2/20 | 0.50 |
| ▸ | SKP1 | P63208 | 2/20 | 0.50 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PGK1 | P00558 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24641499 | 0.87 | DDB1 (0.54) | DDB1CRBNWNT3AGPR119CKS1B | |
| SCHEMBL22279091 | 0.83 | WNT3A (0.56) | DDB1CRBNWNT3AGPR119CKS1B | |
| SCHEMBL25198223 | 0.83 | MEN1 (0.46) | DDB1CRBNSMN1; SMN2MAPTMEN1 | |
| SCHEMBL24590342 | 0.83 | DDB1 (0.63) | DDB1CRBNWNT3AGPR119CKS1B | |
| SCHEMBL31627702 | 0.81 | GPR119 (0.58) | DDB1CRBNWNT3AGPR119CKS1B | |
| SCHEMBL30893577 | 0.81 | DDB1 (0.57) | DDB1CRBNWNT3AGPR119CKS1B | |
| SCHEMBL1905470 | 0.81 | DDB1 (0.57) | DDB1CRBNWNT3AGPR119CKS1B | |
| SCHEMBL25404236 | 0.80 | MEN1 (0.46) | GPR119SMN1; SMN2MAPTMEN1TSHR | |
| SCHEMBL30261848 | 0.79 | DDB1 (0.62) | DDB1CRBNWNT3AGPR119CKS1B | |
| SCHEMBL28956351 | 0.79 | DDB1 (0.62) | DDB1CRBNWNT3AGPR119CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| US-12454521-B2 | Targeted protein degradation | C4 THERAPEUTICS, INC. | 2025-10-28 | — | — | US | disclosed |
| CN-117157298-A | Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase 4, preparation method, medicinal composition and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-11-24 | — | — | US | disclosed |
| EP-3897631-A1 | TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453679-A | Targeted protein degradation | C4医药公司 | 2021-09-28 | — | — | CN | disclosed |
| WO-2020132561-A1 | TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015338-A1 | TARGETED PROTEIN DEGRADATION | PSMC3, PSMA6, ADRM1 | DDB1 716/4885CRBN 17/4885WNT3A 1308/4885 |
| US-20220372016-A1 | TARGETED PROTEIN DEGRADATION | STUB1, MDM2, UBE3A | DDB1 219/4885CRBN 55/4885WNT3A 1490/4885 |
| US-12454521-B2 | Targeted protein degradation | STUB1, MDM2, UBE3A | DDB1 219/4885CRBN 55/4885WNT3A 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.